Challenges facing pathologists evaluating PD‐L1 in head & neck squamous cell carcinoma
Volume: 50, Issue: 9, Pages: 864 - 873
Published: Jul 8, 2021
Abstract
Programmed death-ligand 1 (PD-L1) expression with combined positive score (CPS) ≥1 is required for administration of checkpoint inhibitor therapy in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The 22C3 pharmDx Dako immunohistochemical assay is the one approved as companion diagnostic for pembrolizumab, but many laboratories work on other platforms and/or with other clones, and studies exploring the potential...
Paper Details
Title
Challenges facing pathologists evaluating PD‐L1 in head & neck squamous cell carcinoma
Published Date
Jul 8, 2021
Volume
50
Issue
9
Pages
864 - 873
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History